Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Lymphoid 7Breast 7Tumor-Agnostic 5Plasma cell 5Myeloid 5Gynecologic 5CNS 5Gastrointestinal 4Dermatologic 4Sarcoma 2Genitourinary 2Other solid neoplasm 1Other neoplasm 1Head & Neck 1

Conditions

Pediatric Solid Tumor, Unspecified, Protocol Specific 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ondansetron × Other solid neoplasm × Clear all
NCT06208917 2024-01-17

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

Sun Yat-sen University

Phase 3 Recruiting
376 enrolled
Other solid neoplasm

Pediatric Solid Tumor, Unspecified, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡